CEConversations

This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.

Supported through an independent educational grant from EQRx International, Inc.

Presented by Creative Educational Concepts, LLC.

Learning Objectives

• Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.
• Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC. 
• Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
• Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care.   
   

Supported by independent educational grant from Gilead.

Presented by Creative Educational Concepts, LLC.

This symposium will explore the latest ovarian cancer guideline recommendations and recent evidence for PARP inhibitors in treatment and maintenance settings. The nurse’s role in facilitating access to quality care for those with disparities, the unique toxicity profiles of PARP inhibitors, and how to mitigate, anticipate, and manage toxicities that may arise will also be discussed. Attendees will interact with the expert faculty through patient cases with audience response questions incorporated throughout.

Supported through an independent educational grant from GlaxoSmithKline.

Presented by Creative Educational Concepts, LLC.

This activity will review the failure rates of traditional therapies for DLBCL, such as R-CHOP, and evaluate patient-centric factors that contribute to disease progression and/or relapse. Expert faculty will then guide attendees through an evidence-based examination of the exigent need for more effective front-line therapeutic options in DLBCL, emphasizing practical clinical pearls and notable distinguishing features of novel and emerging treatment agents and their potential to optimize patient outcomes.

Supported by an independent educational grant from Genentech.

This activity will review how social determinants of health have led to inequities and disparate outcomes in HF. Attendees will take part in an expert-led exploration of current treatment guidelines, with an emphasis on HFrEF, and a review of emerging novel therapeutics. Learners will review real-world cases, empowering them to effectively interpolate novel agents into established guideline-directed medical therapy (GDMT) protocols and promote the closure of outcomes chasms driven by disparities in care.

Supported by an independent educational grant from Merck.

Credit is no longer available, however, you can still access and learn from this podcast!

This Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like cancer, and the resultant rationale for the preferential use of intravenous (IV) iron versus oral iron modalities in patients with cancer. Finally, the preeminent emphasis of the session will be an incisive exploration of completed, ongoing, and planned clinical trials of IV iron for CRA/CIA, including systematic reviews and meta-analyses, as well as recently-reported pivotal trials, such as IRON-CLAD.

Supported through an independent educational grant from American Regent.

Our hosts interview two pharmacists, both of whom have expertise in the realms of vaccine supply chain management, distribution, and administration, regarding the myriad challenges and practical hurdles posed by a global pandemic - and key strategies to overcome them. 

Guests:
Joel Thornbury, President, Kentucky Pharmacists Association (KPhA); Owner, Nova Pharmacy;
Brooke Hudspeth, PharmD, Associate Professor and Chief Practice Officer, University of Kentucky College of Pharmacy

Our hosts interview an immunology researcher and vaccine expert regarding how effectively harnessing the immune system possesses the power to defeat the pandemic and restore normalcy to the world.
Practical issues, such as the role of health inequities and social determinants of health, and how/when we can safely travel the world or simply eat at the restaurant down the street, are also addressed.

Guest:
Vincent Venditto, PhD
Assistant Professor
University of Kentucky College of Pharmacy

An infectious disease pharmacist and an immunology specialty pharmacist discuss current and emerging data about COVID-19 with a renowned virologist. They review where we've been, the current state of affairs as the vaccine supply chain is stretched to capacity on an international scale, and perhaps most importantly--where we can expect to be in 6 months.

Episode Guest: Rebecca Dutch, PhD (Hosts: Craig Martin, PharmD, MBA; Dave Feola, PharmD, PhD)